The Effect of Bevacizumab (Avastin) on Pterygium

The University of Alabama at Birmingham

Status and phase: Completed; Phase 2

Conditions: Pterygium

Treatments: Drug: local injection of bevacizumab

Study type: Interventional

Funder types: Other

Identifiers

NCT00592176

F070323011

Details and patient eligibility

About

The purpose of this study is to determine whether local injection of bevacizumab might halt and or cause regression of pterygium growth. This may enable earlier treatment and prevention of pterygium growth into the patient's line of sight thereby limiting the need for surgery and improving quality of life for patients with pterygia.

Enrollment: 5 patients

Sex: All

Ages: 19+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• 19 years of age and older
• Diagnosis of pterygia
• healthy enough to make scheduled follow-up visits

Exclusion criteria

• Women of childbearing potential and males who plan to father a child during their participation in the study will be excluded from the study.

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

5 participants in 1 patient group

Bevacizumab

Experimental group

Description:

Bevacizumab injection: 0.1ml, 6 monthly doses plus baseline and 1 week post baseline

Treatment:

Drug: local injection of bevacizumab